Medical Policy and Coding Updates - December 2023
Summary
Effective March 17, 2024, Carelon Medical Benefits Management Genetic Testing Clinical Appropriateness Guidelines (formerly AIM Specialty Health) replaced contraindicated with unsafe or infeasible for tissue biopsy in cell-free DNA testing, restricted somatic tumor testing to 50 genes or less for several cancers and leukemias, and removed the Afirma standalone assay for indeterminate thyroid nodules. Effective December 1, 2023, the Whole Body Dual X-Ray Absorptiometry and Bioelectrical Impedance Analysis to Determine Body Composition policy (6.01.528) states that whole-body dual energy X-ray absorptiometry or bioelectrical impedance analysis for body composition studies is investigational for all indications. Effective December 1, 2023, Premera HMO specified that inpatient mental health medical evaluations must be done by a physician, nurse practitioner, or physician assistant, or be done in an emergency department or hospital inpatient medical unit before direct transfer to the inpatient facility.
Get alerts when payers change rules like this one
We check Premera Blue Cross and other payers every day and email you when a change matches your specialty and state.